Merck price target raised to $122 from $116 at Truist

Truist raised the firm’s price target on Merck to $122 from $116 and keeps a Buy rating on the shares after its Q2 results. The company’s base business is continuing to support growth as Merck executes on key products such as Keytruda/Gardasil, the analyst tells investors in a research note. Truist adds that it sees next leg of growth for the company coming from Cardiovascular Disease and Inflammation and Immunology programs.